Publications internationales
Nous mettons ici à votre disposition une sélection de publications scientifiques en rapport avec l'immunothérapie IOZK.
Vous pouvez effectuer une sélection par type de tumeur et par méthode à l'aide des filtres ou saisir des termes de recherche.
Virus combinations and chemotherapy for the treatment of human cancers
Oncolytic virotherapy as a personalized cancer vaccine
Dendritic cell vaccines in metastasized malignant melanoma
Regional hyperthermia of the abdomen in conjunction with chemotherapy for peritoneal carcinomatosis: evaluation of two annular-phased-array applicators
Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia
[Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide]
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
Inoperable Pancoast tumors treated with hyperthermia-inclusive multimodality therapies
TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis
Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C)
Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2
Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer
CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo
Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells
Regional hyperthermia in high-risk soft tissue sarcomas
Maximizing dendritic cell migration in cancer immunotherapy
Strategies to overcome obstacles to successful immunotherapy of melanoma
Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma